Reversible diplopia induced by high-dose intravenous IL-2 therapy.
Bharadwaj
Jayaram S
JS
The University of Utah Cancer Immunotherapy Program, UT, USA.
Blumenthal
Deborah T
DT
Samlowski
Wolfram E
WE
D000368:Aged; D001763:Blepharoptosis / Q000139:chemically induced; D001929:Brain Edema / Q000139:chemically induced; D004172:Diplopia / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D008578:Meninges / Q000187:drug effects / Q000473:pathology
D007155:Immunologic Factors; D007376:Interleukin-2